Occupational Exposure to Polycyclic Aromatic Hydrocarbons and Lung Cancer Risk: Results from a Pooled Analysis of Case-Control Studies (SYNERGY).


Journal

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608

Informations de publication

Date de publication:
01 07 2022
Historique:
received: 17 12 2021
revised: 22 03 2022
accepted: 11 04 2022
pubmed: 20 4 2022
medline: 6 7 2022
entrez: 19 4 2022
Statut: ppublish

Résumé

Exposure to polycyclic aromatic hydrocarbons (PAH) occurs widely in occupational settings. We investigated the association between occupational exposure to PAH and lung cancer risk and joint effects with smoking within the SYNERGY project. We pooled 14 case-control studies with information on lifetime occupational and smoking histories conducted between 1985 and 2010 in Europe and Canada. Exposure to benzo[a]pyrene (BaP) was used as a proxy of PAH and estimated from a quantitative general population job-exposure matrix. Multivariable unconditional logistic regression models, adjusted for smoking and exposure to other occupational lung carcinogens, estimated ORs, and 95% confidence intervals (CI). We included 16,901 lung cancer cases and 20,965 frequency-matched controls. Adjusted OR for PAH exposure (ever) was 1.08 (CI, 1.02-1.15) in men and 1.20 (CI, 1.04-1.38) in women. When stratified by smoking status and histologic subtype, the OR for cumulative exposure ≥0.24 BaP μg/m3-years in men was higher in never smokers overall [1.31 (CI, 0.98-1.75)], for small cell [2.53 (CI, 1.28-4.99)] and squamous cell cancers [1.33 (CI, 0.80-2.21)]. Joint effects between PAH and smoking were observed. Restricting analysis to the most recent studies showed no increased risk. Elevated lung cancer risk associated with PAH exposure was observed in both sexes, particularly for small cell and squamous cell cancers, after accounting for cigarette smoking and exposure to other occupational lung carcinogens. The lack of association between PAH and lung cancer in more recent studies merits further research under today's exposure conditions and worker protection measures.

Sections du résumé

BACKGROUND
Exposure to polycyclic aromatic hydrocarbons (PAH) occurs widely in occupational settings. We investigated the association between occupational exposure to PAH and lung cancer risk and joint effects with smoking within the SYNERGY project.
METHODS
We pooled 14 case-control studies with information on lifetime occupational and smoking histories conducted between 1985 and 2010 in Europe and Canada. Exposure to benzo[a]pyrene (BaP) was used as a proxy of PAH and estimated from a quantitative general population job-exposure matrix. Multivariable unconditional logistic regression models, adjusted for smoking and exposure to other occupational lung carcinogens, estimated ORs, and 95% confidence intervals (CI).
RESULTS
We included 16,901 lung cancer cases and 20,965 frequency-matched controls. Adjusted OR for PAH exposure (ever) was 1.08 (CI, 1.02-1.15) in men and 1.20 (CI, 1.04-1.38) in women. When stratified by smoking status and histologic subtype, the OR for cumulative exposure ≥0.24 BaP μg/m3-years in men was higher in never smokers overall [1.31 (CI, 0.98-1.75)], for small cell [2.53 (CI, 1.28-4.99)] and squamous cell cancers [1.33 (CI, 0.80-2.21)]. Joint effects between PAH and smoking were observed. Restricting analysis to the most recent studies showed no increased risk.
CONCLUSIONS
Elevated lung cancer risk associated with PAH exposure was observed in both sexes, particularly for small cell and squamous cell cancers, after accounting for cigarette smoking and exposure to other occupational lung carcinogens.
IMPACT
The lack of association between PAH and lung cancer in more recent studies merits further research under today's exposure conditions and worker protection measures.

Identifiants

pubmed: 35437574
pii: 694483
doi: 10.1158/1055-9965.EPI-21-1428
pmc: PMC9377765
doi:

Substances chimiques

Carcinogens 0
Polycyclic Aromatic Hydrocarbons 0

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1433-1441

Informations de copyright

©2022 The Authors; Published by the American Association for Cancer Research.

Références

Int J Occup Environ Health. 1998 Oct-Dec;4(4):236-40
pubmed: 9876632
Carcinogenesis. 2012 May;33(5):1059-64
pubmed: 22382497
Lancet Oncol. 2005 Dec;6(12):931-2
pubmed: 16353404
Epidemiology. 2017 Mar;28(2):288-299
pubmed: 28141674
Lung Cancer. 2011 Mar;71(3):264-70
pubmed: 20951464
Occup Environ Med. 2009 Nov;66(11):740-6
pubmed: 19546103
Environ Health Perspect. 2002 Jun;110 Suppl 3:451-88
pubmed: 12060843
Epidemiol Prev. 2001 Jul-Oct;25(4-5):215-21
pubmed: 11789462
Am J Epidemiol. 2007 Mar 15;165(6):634-42
pubmed: 17189590
Environ Int. 2019 Mar;124:109-120
pubmed: 30641254
Int J Cancer. 2006 Aug 15;119(4):741-4
pubmed: 16557573
Cancer Causes Control. 2004 Jun;15(5):445-52
pubmed: 15286464
Environ Health Perspect. 2004 Jun;112(9):970-8
pubmed: 15198916
Environ Health Perspect. 2004 Dec;112(17):1691-6
pubmed: 15579415
Occup Environ Med. 2002 Sep;59(9):575-93; discussion 594
pubmed: 12205230
Ann Occup Hyg. 2012 Jan;56(1):70-9
pubmed: 21989165
Am J Epidemiol. 2012 Oct 1;176(7):573-85
pubmed: 22986146
Nutr Cancer. 2003;46(1):30-7
pubmed: 12925301
J Occup Environ Med. 2011 Sep;53(9):1068-77
pubmed: 21866050
Am J Respir Crit Care Med. 2020 Aug 1;202(3):412-421
pubmed: 32330394
Environ Mol Mutagen. 2014 Jul;55(6):472-81
pubmed: 24668722
Am J Epidemiol. 2000 Feb 15;151(4):384-95
pubmed: 10695597
IARC Monogr Eval Carcinog Risks Hum. 2010;92:1-853
pubmed: 21141735
Int J Epidemiol. 1998 Aug;27(4):549-60
pubmed: 9758106
Am J Epidemiol. 2010 Feb 1;171(3):323-33
pubmed: 20047975
Int J Epidemiol. 1997;26 Suppl 1:S6-14
pubmed: 9126529
Cancer Causes Control. 2004 Apr;15(3):285-94
pubmed: 15090723
Ann Oncol. 2007 Mar;18(3):431-46
pubmed: 16936186
Am J Respir Crit Care Med. 2020 Aug 1;202(3):402-411
pubmed: 32330395
Ann Occup Hyg. 2016 Aug;60(7):795-811
pubmed: 27286764
Am J Epidemiol. 2000 Jul 1;152(1):32-40
pubmed: 10901327
BMC Cancer. 2007 Aug 16;7:162
pubmed: 17705814
Carcinogenesis. 2002 Sep;23(9):1475-81
pubmed: 12189190
Cancer Causes Control. 1997 May;8(3):444-72
pubmed: 9498904

Auteurs

Ann Olsson (A)

International Agency for Research on Cancer (IARC/WHO), Lyon, France.

Neela Guha (N)

Office of Environmental Health Hazard Assessment, California Environmental Protection Agency, Oakland, California.

Liacine Bouaoun (L)

International Agency for Research on Cancer (IARC/WHO), Lyon, France.

Hans Kromhout (H)

Institute for Risk Assessment Sciences, Utrecht University, Utrecht, the Netherlands.

Susan Peters (S)

Institute for Risk Assessment Sciences, Utrecht University, Utrecht, the Netherlands.

Jack Siemiatycki (J)

Department of Social and Preventive Medicine, University of Montreal, Montreal, Canada.

Vikki Ho (V)

Department of Social and Preventive Medicine, University of Montreal, Montreal, Canada.

Per Gustavsson (P)

Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

Paolo Boffetta (P)

Stony Brook Cancer Center, Stony Brook University, Stony Brook, New York.
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Roel Vermeulen (R)

Institute for Risk Assessment Sciences, Utrecht University, Utrecht, the Netherlands.

Thomas Behrens (T)

Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University (IPA), Bochum, Germany.

Thomas Brüning (T)

Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University (IPA), Bochum, Germany.

Benjamin Kendzia (B)

Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University (IPA), Bochum, Germany.

Pascal Guénel (P)

Center for research in Epidemiology and Population Health (CESP), Exposome and Heredity team, Inserm U1018, University Paris-Saclay, Villejuif, France.

Danièle Luce (D)

Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Pointe-à-Pitre, France.

Stefan Karrasch (S)

Institute and Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, Munich, Germany.
Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany.
Institute of Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany.

Heinz-Erich Wichmann (HE)

Institute of Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany.
Institut für Medizinische Informatik Biometrie Epidemiologie, Ludwig Maximilians University, Munich, Germany.

Dario Consonni (D)

Epidemiology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Maria Teresa Landi (MT)

Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.

Neil E Caporaso (NE)

Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.

Franco Merletti (F)

Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.

Dario Mirabelli (D)

Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.

Lorenzo Richiardi (L)

Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.

Karl-Heinz Jöckel (KH)

Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), University Hospital Essen, Essen, Germany.

Wolfgang Ahrens (W)

Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.
Faculty of Mathematics and Computer Science, Institute of Statistics, University of Bremen, Bremen, Germany.

Hermann Pohlabeln (H)

Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.

Adonina Tardón (A)

Department of Public Health, University of Oviedo. ISPA and CIBERESP, Oviedo, Spain.

David Zaridze (D)

Department of cancer epidemiology and Prevention, N.N. Blokhin National Research Centre of oncology, Moscow, Russia.

John K Field (JK)

Roy Castle Lung Cancer Research Programme, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.

Jolanta Lissowska (J)

Epidemiology Unit, Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.

Beata Świątkowska (B)

Department of Environmental Epidemiology, The Nofer Institute of Occupational Medicine, Lodz, Poland.

John R McLaughlin (JR)

Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.

Paul A Demers (PA)

Occupational Cancer Research Centre, Ontario Health, Toronto, Canada.

Vladimir Bencko (V)

Institute of Hygiene and Epidemiology, First Faculty of Medicine, Charles University, Prague, Czechia.

Lenka Foretova (L)

Masaryk Memorial Cancer Institute, Brno, Czechia.

Vladimir Janout (V)

Faculty of Health Sciences, Palacky University, Olomouc, Czechia.

Tamás Pándics (T)

National Public Health Center, Budapest, Hungary.

Eleonora Fabianova (E)

Regional Authority of Public Health, Banská Bystrica, Slovakia.
Faculty of Health, Catholic University, Ružomberok, Slovakia.

Dana Mates (D)

National Institute of Public Health, Bucharest, Romania.

Francesco Forastiere (F)

Department of Epidemiology, ASL Roma E, Rome, Italy.

Bas Bueno-de-Mesquita (B)

Former senior scientist, Centre for Nutrition, Prevention and Health Services, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.

Joachim Schüz (J)

International Agency for Research on Cancer (IARC/WHO), Lyon, France.

Kurt Straif (K)

ISGlobal, Barcelona, Spain.
Boston College, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH